Press Room - Sanofi US News
WEB2 days ago · SARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sanofi moves on J&J in first-line myeloma with FDA nod
WEB2 days ago · ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of J&J's multiple myeloma shadow. Challenging Darzalex won’t be easy. Worldwide sales of the J&J med jumped 22% and reached $9. ...
Sanofi wins US approval for multiple myeloma drug in newly …
WEB2 days ago · Sarclisa generated sales of 227 million euros ($253.40 million)in the first half of the year. Analysts expect annual Sarclisa sales of about 800 million-900 million euros by 2030, according to ...
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible …
WEB2 days ago · Sarclisa was approved by the FDA in 2020 in combination with pomalidomide and dexamethasone for adults with multiple myeloma who received at least two prior therapies including lenalidomide and a proteasome inhibitor. In 2021, it was approved by the agency in combination with Kyprolis (carfilzomib) and dexamethasone to …
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB1 day ago · In the IMROZ study, Sarclisa-VRd followed by Sarclisa-Rd met the primary endpoint of PFS, significantly reducing the risk of recurrence or death by 40%, compared to VRd followed by Rd, in patients ...
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB2 days ago · The FDA approved isatuximab (Sarclisa; Sanofi-Aventis) with bortezomib, lenalidomide, and dexamethasone (VRd) for adults who cannot receive autologous stem cell transplant to treat their newly ...
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sanofi wins US approval for multiple myeloma drug in newly …
WEB2 days ago · -The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed multiple myeloma patients. Sarclisa has previously been approved for use as a fallback therapy for certain cases of multiple myeloma after standard treatments have failed. The French drugmaker, a market ...
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer ...
WEB2 days ago · The French pharmaceutical company said Sarclisa was approved in combination with bortezomib, lenalidomide and dexamethasone. Multiple myeloma is a blood cancer that develops in plasma cells. The ...
Skip to content